Portage Biotech and Biohaven Pharmaceuticals recently announced they have received positive feedback from the U.S. Food and Drug Administration (FDA) on their Pre-Investigational New Drug Application (PIND) interaction regarding Biohaven’s investigative drug BHV-0223, intended for treatment of amyotrophic lateral sclerosis (ALS). BHV-0223 is the glutamate modulating compound riluzole, contained in the tablet…

“ALS is a fatal, neurodegenerative disease that attacks nerve cells and pathways in the brain and spinal cord and slowly robs the body of its ability to speak, swallow and breathe. In the United States, a person is diagnosed with ALS every 90 minutes. The ALS Association St. Louis…

In this 2009 WLUK-TV FOX 11 story, meet “Peggy Driessen who has ALS, or Lou Gehrig’s Disease. She gets through each day with a positive attitude — and a lot of help from loved ones.” Learn more about ALS here: https://bit.ly/ALSNewsToday…

In a new study, researchers found a protein in the p53 family, called p63, is increased in amyotrophic lateral sclerosis (ALS) and is a significant player in disease progression through the regulation of the activity of genes that promote the breakdown of muscle cells. The study, “Transcriptional activator TAp63 is upregulated in muscular atrophy during…

“Meet Jim Barber, one of the four people with amyotrophic lateral sclerosis (ALS) honored by the ALS Association, in February 2016, for their extraordinary efforts in making a difference for the ALS community.” Read more on ALS here: https://bit.ly/1RmVMwo…

Researchers revealed that the loss of major histocompatibility complex I (MHCI) is a key step in the development of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease). The study, “Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis,” was published in the journal…

In this Project ALS video, learn more about ALS, also known as Lou Gehrig’s disease. ALS is a brain disease which is closely related to Parkinson’s, Alzheimer’s, and Huntington’s diseases. ALS targets cells in the brain and spinal cord called motor neurons. In ALS, as motor neurons die, a…

Cytokinetics announced that it has joined with efforts by the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to raise awareness for Rare Disease Day. Cytokinetics is focused on discovering, developing, and commercializing new types of muscle activators, and has developed the amyotrophic lateral sclerosis (ALS) drug candidate…

Meet Nanci Ryder, one of the four people with amyotrophic lateral Sclerosis (ALS) honored by the ALS Association, in February 2016, for their extraordinary efforts in making a difference for the ALS community. Read more on ALS here: https://bit.ly/1RmVMwo…

Last week’s hot topic on ALS was an article titled Simplesa Expands ‘Deanna Protocol’ Diet Supplement Choices for ALS Patients written by Carolina Henriques. The article is focused on the expansion of the Deanna Protocol Bundle Pack choices for consumers by Simplesa, a nutrition…